Mean (SD) SF12 Physical Component Score (PCS) and median (IQR) Mental Component Score (MCS) at baseline and 6-month follow-up and difference between the two assessment points for each arm, prescribing, review and treatment as usual (TAU)
| Prescribing | Review | TAU | |||||
|---|---|---|---|---|---|---|---|
| N* | Mean (SD) | N* | Mean (SD) | N* | Mean (SD) | p Value (between groups†) | |
| Baseline SF-12 PCS | 41 | 33.5 (10.8) | 43 | 32.59 (11.38) | 45 | 29.60 (9.71) | |
| 6-month follow-up SF12 PCS | 35.3 (10.8) | 34.62 (11.26) | 32.59 (9.14) | ||||
| Difference SF-12 PCS | 1.8 (7.5) | 2.02 (7.56) | 2.99 (8.11) | ||||
| p (within groups‡) | 0.12 | 0.09 | 0.02 | 0.75 | |||
| Effect size (r) | 0.24 | 0.26 | 0.35 | ||||
| Median (IQR) | Median (IQR) | Median (IQR) | |||||
| Baseline SF-12 MCS | 42 | 52.4 (42.0;58.8) | 43 | 47.9 (38.5;59.9) | 45 | 51.5 (41.3;60.7) | |
| 6-month follow-up SF-12 MCS | 49.6 (42.8;58.1) | 47.9 (38.9;56.2) | 44.7 (37.6;55.8) | ||||
| Difference SF-12 MCS | −0.4 (−3.7;6.0) | −1.2 (−6.6;4.2) | −3.0 (−10.0;1.3) | ||||
| p (within groups‡) | 0.64 | 0.37 | 0.002 | 0.04 | |||
| Effect size (r) | 0.07 | 0.14 | 0.46 |
Within-arm and between-arm p values are also reported.
*Number of participants in each group who completed the appropriate part of the SF-12 at both baseline and follow-up.
†From analysis of variance on mean difference or Kruskall-Wallis test on median difference as appropriate.
‡From paired t test or Wilcoxon signed rank test as appropriate.